Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1998; 32:665-672
© 1998 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, A. S.
Right arrow Articles by Black, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, A. S.
Right arrow Articles by Black, D. M.

Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin

Alan S. Brown, MD*, Rebecca G. Bakker-Arkema, MS**, Laurence Yellen, MD{dagger}, Robert W. Henley, Jr., MD{ddagger}, Richard Guthrie, MD§, Cam F. Campbell, MD||, Michael Koren, MD, William Woo, MD#, Richard McLain, MS** and Donald M. Black, MD**

* Midwest Heart Research Foundation, Naperville, Illinois, USA
{dagger} Cardiology Associates Medical Group, San Diego, California, USA
{ddagger} Cardiovascular Associates of Virginia, Richmond, Virginia, USA
§ St. Paul Heart Clinic, St. Paul, Minnesota, USA
|| Iowa City Heart Center, Iowa City, Iowa, USA
Jacksonville Cardiovascular Clinic, Jacksonville, Florida, USA
# University of Washington Medical School, Seattle, Washington, USA
** Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Co, Ann Arbor, Michigan, USA



View larger version (19K):

[in a new window]
 
Figure 1 Study design. BID = administered twice daily; QD = administered once daily.

 


View larger version (34K):

[in a new window]
 
Figure 2 Dose distribution by percentages of patients in each treatment group at week 54 (with the last available observation carried forward). Starting dose: 10 mg atorvastatin and simvastatin; 20 mg fluvastatin and lovastatin. All other monotherapy doses: 20 to 80 mg atorvastatin; 40 mg fluvastatin; 40 to 80 mg lovastatin; 20 to 40 mg simvastatin. Highest dose plus colestipol (up to 20 g/day): 80 mg atorvastatin and lovastatin; 40 mg fluvastatin and simvastatin. White portion = starting dose; gray portion = all other monotherapy doses; black portion = highest dose of reductase inhibitors plus colestipol.

 


View larger version (20K):

[in a new window]
 
Figure 3 Cumulative percentage of patients reaching the NCEP-recommended LDL cholesterol goal (≤100 mg/dl). The median dose for each treatment group at week 54 (with the last available observation carried forward) was atorvastatin 20 mg/day, fluvastatin 40 mg/day plus colestipol 20 g/day, lovastatin 80 mg/day and simvastatin 40 mg/day.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement